TELA Bio Inc（TELA）財務資料TELATELA Bio Inc

TELA Bio Inc (TELA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OviTex, accounting for 69.0% of total sales, equivalent to $13.31M. Other significant revenue streams include OviTex PRS and Other. Understanding this composition is critical for investors evaluating how TELA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, TELA Bio Inc maintains a gross margin of 69.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -51.23%, while the net margin is -58.38%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TELA converts its operational activities into shareholder value.

In the context of the broader market, TELA competes directly with industry leaders such as XTLB and ARAY. With a market capitalization of $33.13M, it holds a leading position in the sector. When comparing efficiency, TELA's gross margin of 69.17% stands against XTLB's N/A and ARAY's 34.76%. Such benchmarking helps identify whether TELA Bio Inc is trading at a premium or discount relative to its financial performance.

In Q2 2026, TELA Bio reported total revenue of $19.29 million, with a gross margin of 69.17%. Despite these figures, the company has been operating at a loss, with a net income of -$11.26 million.